Tower Research Capital (TRC)’s Kite Pharma, Inc. KITE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-4,039
Closed -$726K 4456
2017
Q3
$726K Buy
+4,039
New +$563K 0.06% 181
2017
Q1
Sell
-4,938
Closed -$222K 4494
2016
Q4
$222K Buy
+4,938
New +$242K 0.02% 594
2016
Q1
Sell
-950
Closed -$59K 5490
2015
Q4
$59K Sell
950
-592
-38% -$41.7K 0.01% 485
2015
Q3
$85K Buy
1,542
+321
+26% +$20.2K 0.01% 658
2015
Q2
$74K Buy
1,221
+620
+103% +$35.4K 0.01% 1080
2015
Q1
$35K Buy
+601
New +$40.3K ﹤0.01% 1779
2014
Q4
Sell
-249
Closed -$7K 5146
2014
Q3
$7K Buy
+249
New +$6.16K ﹤0.01% 3109

Tower Research Capital (TRC)'s KITE Position: Q4 2017 in Review

Tower Research Capital (TRC) sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 4,039 shares — an estimated $726K sold.

Tower Research Capital (TRC) first reported a position in KITE in Q3 2014 and held it in 7 quarters. The position peaked at $726K in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Tower Research Capital (TRC) reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 4,039 Kite Pharma, Inc. shares in Q4 2017, an estimated $726K.
  • Tower Research Capital (TRC) first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 7 quarters.
  • Tower Research Capital (TRC)'s Kite Pharma, Inc. position peaked at $726K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2017, filed 9 Feb 2018.